When are you recommending bone marrow transplant recipients receive the SARS-CoV-2 vaccine?

The CIBMTR and EBMT data indicate a 20-30% mortality in transplant patients. Risk factors are age >50, male, and <12 months from HSCT. Unfortunately, the complexity of immunological recovery after transplant makes inferring the likelihood of response to a new vaccine formulation impossible. In general, we do not see much of an antibody response to conventional vaccines early in the transplant. Typically, vaccines are given some time between 6 and 9 months (we start at 9 months) and there is a subsequent schedule such that there are boosters at 12 and 18 months as well as new vaccines introduced at various times. Even then there are gaps in coverage, and we have had severe pneumococcal sepsis in patients without GVHD who were fully vaccinate...

Our current practice is to offer the COVID-19 vaccine to our transplant patients 3 months after auto and allo SCT or 6 weeks prior to auto SCT. I agree with Dr. @Dr. First Last, we don't have much data yet.

https://www.myast.org/sites/default/files/2021%2001%2025%20COVID19%20VACCINE%20FAQS_update%20v%203.pdf